Trial Profile
Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2023
Price :
$35
*
At a glance
- Drugs Fostemsavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Bristol-Myers Squibb; ViiV Healthcare
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
- 23 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.